Canada: The Supreme Court Refuses To Grant Leave To Hear "Promise Of The Patent" Appeals

Last Updated: April 30 2015
Article by Adam Bobker and Teresa MacLean

On April 23, 2015, the Supreme Court of Canada denied leave to hear an appeal from the Federal Court of Appeal decision in Apotex Inc v Pfizer Canada Inc, et al and Mylan Pharmaceuticals ULC v Pfizer Canada Inc, et al, 2014 FCA 250 (the Court of Appeal decision). As there has been much discussion in the area of law surrounding utility and the "promise of the patent", guidance from the Supreme Court of Canada would have been welcome. However, the decision reached by the Federal Court of Appeal in this case takes a balanced approach to determining whether a patent contains an invalidating unfulfilled promise.

The leave applications relate to Canadian Patent No. 2,177,576 (the '576 Patent), which expired on November 14, 2014. The '576 Patent was directed to a new class of non-steroidal anti-inflammatory drugs (NSAIDs) and claimed new compounds including celecoxib, sold by Pfizer under the name Celebrex, and their associated uses. Pfizer sought orders prohibiting the Minister of Health from issuing a Notice of Compliance to Apotex and to Mylan in respect of their generic versions of the drug Celebrex. The Federal Court allowed both of Pfizer's applications and issued prohibition orders against Mylan (2014 FC 38) and Apotex (2014 FC 314). Apotex and Mylan appealed the orders. The appeals were consolidated and refused by the Federal Court of Appeal.

Apotex advanced four distinct arguments before the Court of Appeal: i) lack of utility in treating inflammation in humans, ii) lack of utility in reducing side effects, iii) lack of utility in preventing colorectal cancer, and iv) insufficient disclosure. Mylan's submissions focused on an argument of lack of utility in reducing side effects. The parties also alleged that the Federal Court breached the principles of comity and stare decisis in failing to follow the construction of the '576 Patent reached by Justice Hughes in GD Searle & Co v Novopharm Ltd (2007 FC 81) and affirmed by the FCA (2007 FCA 173). Further, the parties argued that it was abuse of process for the Federal Court judge to accept Pfizer's pleading that reduced harmful side effects were not promised as it had conceded that point in the Novopharm decision.

Justice Noël began his analysis by stating that the minimum statutory requirements for utility are quite low - no more than a "scintilla" - and the promise doctrine is an exception to this standard. An inventor need not describe any particular utility and will be held to a higher utility standard only where a "clear and unambiguous" promise has been made. Further, when allegations of unfulfilled promises regarding a patent are made, the patent will be construed in the patentee's favour where it can reasonably be read by a skilled person to exclude any such promises.

Apotex argued that where a patent "lays claim" to a particular use, that use must form part of the promise. Justice Noël rejected this broad proposition, stating "when a result or advantage is asserted in a patent's claims, it will generally be seen as a promise of utility." Apotex had failed to establish that any of the '576 Patent's claims describe use in humans as an advantage of the claimed compounds and the '576 Patent made no explicit promise of treatment in humans. Justice Noël also rejected the parties assertions that the '576 Patent promised utility in reducing side effects.

Apotex further argued that any given promise must be construed as overarching and, since the promise of preventing colorectal cancer was neither demonstrated nor soundly predicted as of the filing date, the patent as a whole should be invalidated. The Court of Appeal held that there was no support in the jurisprudence for this proposition. At most, the cases cited by Apotex demonstrate that a promise may be construed to extend to each of the patent's claims and there was no general statement of law made on the matter.

Regarding sufficiency of disclosure, Apotex's asserted that Pfizer concealed its "true invention" among a group of compounds that it knew were not useful, resulting in insufficient disclosure. This was rejected since Apotex had not advanced these arguments in its Notice of Allegation.

Additionally, the appellants had argued at the Federal Court that Pfizer was abusing the process of the court as it had conceded in the Novopharm NOC proceeding that reduced side effects were necessary to the utility of the '576 Patent. Apotex asserted that a party cannot elevate an inventive concept to support non-obviousness and read then it down in the utility analysis, that a party cannot take inconsistent positions in different proceedings, and that a party cannot re-litigate an issue previously decided with the aid of additional evidence it chose not to adduce in the earlier proceeding. The Court of Appeal dismissed these arguments, stating that there may be instances where a concession made in one proceeding may be binding in another, but there is no existing precedent on point and Federal Court judge had not committed any error in exercising his discretion to hold otherwise.

Apotex and Mylan further asserted that under the doctrine of stare decisis, the Federal Court was bound by the construction of the '576 Patent reached by Justice Hughes and upheld by the Court of Appeal in the Novopharm decision. There, it was held that a promise of reduced side effects had been made. Justice Noël emphasized that the doctrine of stare decisis obliges courts to render decisions that are consistent with previous decisions made by higher courts. However, not every statement in a given judgment is binding on lower courts. An appellate judgment will be authoritative for its ratio decidendi, the reasoning necessary to reach a decision on the issues litigated. Statements of obiter dicta will vary in authoritative force from helpful commentary to guidance. The Novopharm Court of Appeal decision did not decide that reduced side effects were necessary to the utility of the '576 Patent, rather, it decided two narrow issues relating to the correct claim date and a point of obviousness. Thus, there is no authoritative decision relating to utility of reducing side effects reached by a higher court that would have bound the Federal Court in subsequent litigation.

Regarding the doctrine of comity or horizontal stare decisis, Justice Noël reiterated that decisions reached by judges of the same court are not binding on each other. There may be uncertainty created when two judges reach distinct results on the same question of law. However, there is no legal sanction for a judge's failure to abide by comity.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Adam Bobker
Teresa MacLean
In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.